[A double blind cross-over study with mepindolol-sulfate in patients with coronary heart disease (author's transl)].
The effect of mepindolol-sulfate (2 x 2.5 mg) was tested in 20 patients with coronary heart disease in a controlled study against placebo resp. propranolol (3 x 40 mg).


RESULTS
1. The frequency and intensity of anginal attacks were reduced significantly under mepindolol-sulfate therapy.-- 2. There was a significant improvement of ergometric exercise tolerance under mepindolol-sulfate therapy.--3. Additionally a reduction of ST-depression in ECG was found under mepindolol-sulfate.--4. In patients with coronary heart disease the clinical effect of mepindolol-sulfate in a daily dose of 2 x 2.5 mg was equal to propranolol in a daily dose of 3 x 40 mg.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D003327:Coronary Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D010869:Pindolol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010919:Placebos; D011433:Propranolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D010919:Placebos; D011433:Propranolol; D010869:Pindolol
Therapeutische doppelblinde Cross-over-Studie mit Mepindolol-Sulfat bei Patienten mit koronarer Herzkrankheit.